[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study
about
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancerEmerging PSA-based tests to improve screeningLandmarks in prostate cancer diagnosis: the biomarkersKallikreins as biomarkers for prostate cancerComprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countriesProstate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in AsiaClinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureLongitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first reportPSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.Biomarkers in prostate cancer surveillance and screening: past, present, and future.The Prostate Health Index: a new test for the detection of prostate cancer.Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.Novel biomarkers for the detection of prostate cancer.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.Risk-based prostate cancer screening.From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.Prostate cancer: measuring PSA.Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Commercialized biomarkers: new horizons in prostate cancer diagnostics.Prostate-specific antigen-based prostate cancer screening: Past and future.Clinical Utility of Biomarkers in Localized Prostate Cancer.Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns.Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.Cost-effectiveness of Prostate Health Index for prostate cancer detection.Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA iProstate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy.Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA rangeThe Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.
P2860
Q26824913-FCCE2A2A-C522-4745-A818-ECFA6F656E63Q26828563-1701B05A-0D67-477F-964D-9E0BE6B2A4DEQ26852523-019A9C2F-0E50-4749-BE81-308C5B7E679DQ26862434-D9349E5A-5CDA-4C0D-A636-8B99089F1CAFQ26996461-9CF42822-13D5-4DE7-88CC-C70EE994E48AQ28085419-67E79AAC-B228-4D12-A3B7-56A7FD81E891Q33911725-9AB068E4-0F03-403B-AE35-8AE2AE624AB9Q35816476-272ECB73-4D04-4177-AEA3-27FF17FBFF95Q35838396-F1AB54C2-2ABD-4108-AB17-567D6B4B6231Q35969948-827AFD49-3761-4EBF-9CCB-433C4B0B5BE1Q35993261-378EAC28-D27F-406C-B50F-81E228092350Q35995359-2E899715-4E90-4DC6-B6FC-180F982ACCE7Q36416365-FC060D14-123C-43B9-B9EA-B0EA0186F638Q36416441-09AC7ECD-274B-4FDB-A761-B1B392182732Q36909145-6EE47004-8271-4886-8E71-6B24C0D89844Q37037804-DC8CA629-5BA9-4FC7-A8F2-8363BCAF35EAQ37300931-7C09CF3B-8CCB-4AF5-A5B3-6924C9D81A95Q37619016-AAF34BE8-DC81-4662-B016-98BC5D2DABE2Q37685652-CEFE2341-359A-4C27-8B4E-401D0CE7B64EQ37708174-C0CB87D4-0706-4111-90C3-638FFC83D157Q37738370-C749B519-CB6F-463C-B589-46246ED737FCQ37963657-C315741A-E33A-47F0-85AD-8C87B767DBB2Q38023597-3080A46B-C632-46D5-8107-A22FEDF35CB3Q38210857-DC3BFFC7-69FD-416A-9288-A66C2F4B906CQ38241107-BB489215-DCDE-45FD-9114-3481DE465A5CQ38364797-7C6937CA-3423-4319-8687-86787B8E1855Q38408501-1927CEE7-9644-4F21-A603-841E8F17AFE1Q38792354-C0946CC9-B8D7-4DB2-AFB0-52100B8C5DDFQ39937201-C0B7DC93-3EF3-4811-BD68-0A460BF8DB00Q39968883-17F119DB-9C47-46CC-8140-142A87A26C1EQ40007049-9ABFE6A3-6951-43B6-9373-C96DDBFBEF99Q40140207-40D82AD6-2B05-455C-AB17-DA998F2C0248Q40211476-F8048CA4-71AA-441C-AEA7-C7C0E0611C53Q40267154-A48D8C17-8E1F-4A4F-AF90-6FB28EA62359Q40358939-8596B7EC-F410-4B0A-A258-B5B153F9979AQ40438258-4BB6086E-60CE-4601-B2BD-D8CB96743CCBQ41474330-A2F7B41B-D3DF-4AF0-B78C-CD4C8F427235Q42231619-0ACDFE03-02FB-4945-A5A5-73212250CD14Q45211941-7BB3A839-ED66-4149-9E3B-C725C86B8AC1Q46098777-0D2F8E06-5E9E-44FC-94E3-0E7D19A3B222
P2860
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@ast
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@en
type
label
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@ast
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@en
prefLabel
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@ast
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@en
P2093
P2860
P1476
[-2]Proenzyme prostate specifi ...... rostate cancer screening study
@en
P2093
Brian V Le
Christopher R Griffin
Donghui Kan
Gustavo F Carvalhal
Nikola A Baumann
William J Catalona
P2860
P304
P356
10.1016/J.JURO.2009.12.056
P407
P50
P577
2010-02-19T00:00:00Z